Search PubMed⌕ Search

Biomedical subjects

G Landbeck

Publications and source records attributed to G Landbeck.

At least 37 records · Page 2Linked to original sources
PubMed1983

[Wiskott-Aldrich syndrome].

Current concepts of pathogenesis and therapy of Wiskott-Aldrich syndrome are discussed, along with demonstrating the case history of a patient with the clinical features of this rare disorder. In addition to the known symptoms there was an elevated blood monocyte count together with a decreased total number of lymphocytes. Immunological analysis of the mononuclear cell fraction revealed an imbalance between mature T-cells, "natural-killer"-cells and monocytes.

Child, Preschool↗
PubMed1982

[Immunological classification of acute lymphoblastic leukemias (ALL) in childhood. Origin and clinical significance of phenotypic variability].

Leucemic cells in 54 children with ALL have been typed immunologically by conventional antisera, monoclonal antibodies and receptor tests as c-ALL (62.5%), T-ALL/NHL (18.5%), B-ALL (1.9%) and AUL (16.6%), respectively. The different subtypes showed a noteworthy heterogeneity in receptor patterns which may reflect an arrest in discrete differentiation stages within the maturation pathway of a lymphoid cell population. The characteristic set of clinical symptoms of T-cell neoplasias could once again be confirmed. Of interest is a clear trend for a less favourable outcome in AUL as compared to c-ALL and in NHL versus ALL as a whole, whereas no difference could be found between T-ALL and non T-ALL during therapy. Immunological typing of ALL is of clinical importance as entities with different biological behaviour and, correspondingly, different therapeutical requirements can be distinguished.

Adolescent↗
PubMed1981

[Presentation of the cooperative study COALL-80 on treatment of childhood ALL (author's transl)].

The cooperative study COALL-80 is derived from the BFM-78-study. The aim of the study is a reduction of the initial therapy-morbidity and -mortality without loss of efficacy by omitting asparaginase from the four drug-induction regimen and interposing it between induction- and CNS-therapy phase. The expected two years disease free survival rate of a pilot study will be 82%. This finding is hitherto comparable with the BFM-study results.

Adolescent↗
PubMed1981

[On the chemotherapy of Ewing's sarcoma (author's transl)].

Because of the high incidence of pulmonary and skeletal metastases after only local treatment adjuvant systemic chemotherapy is mandatory in Ewing's sarcoma. The drugs most often used thereby are Actinomycin D, Cyclophosphamid, Anthracyclines and Vincristine. In polychemotherapeutic trials two year disease-free survival rates of 80% and more have been accomplished. The rate of local tumour control after radiotherapy is enhanced by chemotherapy but untoward reactions of bone and soft tissue are also. The extent of radiation portals and time indispensable dose of radiation therefore have to be reviewed again. But in view of debilitating side effects of radio-chemotherapy surgical procedures have to be considered individually.

Bone Neoplasms↗
PubMed1980

[ALL-study series of Hamburg (author's transl)].

From 1971 through 1979 145 newly diagnosed patients with ALL have been treated within a series of consecutive studies. Study I corresponds to branch A of the 1972 DAL study. In the following studies the induction therapy has been escalated stepwise with the continuation therapy remaining mostly unchanged. Thereby the disease free survival rates increased from 75 to 94% after one year and from 32 to 60% after 4 years respectively. CNS-relapse mainly occurred during the second year of treatment. Their incidence rose from 5% to more than 10% in connection with a change in the radiation portal. Since another correction of the portals with special consideration of the paramedian lower border of the skull base no more CNS-relapses have been observed until now. The actual cooperative ALL-study follows a modified BFM-protocol with postponed asparaginase in hoping to achieve reduced initial morbidity and at least equal good survival times.

Child↗
PubMed1979

[Common ALL-associated antigen on cells and in the serum of common ALL patients: clinical relevance and biochemical characterization (author's transl)].

The clinical application of an antiserum recognizing common ALL associated antigen (cALL-AG) is very useful in classifying leukemias and diagnosing bone marrow relapse as well as CNS-leukemia. We could demonstrate that sera of common ALL (cALL) patients contain cALL-AG; its partial biochemical characterization is described. The anti cALL serum (cALL-AS) was raised in rabbits with cALL-cells precoated with rabbit antiserum against normal human lymphocytes. After appropriate absorbtion the cALL-AS was highly specific for cALL cells. The isolation of serum cALL-AG was performed by ammoniumsulfat precipitation, gel chromatography and affinity chromatography on agarose lens culinaris hemagglutinin A (lentil lectin). The apparent molecular-weight of the serum glycoprotein is 125 000. Two cALL-AG active structures could be solubilized from cALL cell membrane. The apparent molecular-weights were calculated to be 55 000 and 110 000.

Antigens, Neoplasm↗
PubMed1978

Partial molecular characterization of an antigenic structure associated to cells of common acute lymphocytic leukaemia (ALL).

A heteroantiserum against common human acute lymphocytic leukaemia (ALL) cells was raised in rabbits. This antiserum was rendered specific for common ALL cells by extensive absorption with different human tissue. A specific antigen associated to common ALL cells was solubilized by sodium deoxycholate from ALL plasma membranes and identified by indirect immunofluorescence. By analytical chromatography, two antigenically active peaks were found. The apparent molecular weights were calculated to be 55,000 and 110,000.

Antigens, Neoplasm↗
PubMed1978

[Conservative therapy of CNS-tumors in children. I. Intrduction (author's transl)].

A successful conservative therapy of brain tumors presupposes an early diagnosis as well as radical tumor removal as far as possible. The previously unisatisfactory results of treatment are still often attributable to late diagnosis. With new diagnostic methods of low risk, e.g. computerized tomography, an earlier begin of therapy should be attainable. Improved results of treatment can be expected only by the cooperation of all regional centers in prospective therapy studies and continuous cooperation of all faculties involved.

Age Factors↗
PubMed1978

[Chemotherapy of brain-tumors in children (author's transl)].

The poor permeability of the blood/brain barrier for most cytostatic agents makes it difficult to achieve an adaequate drug concentration in brain-tumors. This is the main problem in developing a chemotherapy of brain tumours. On the other hand the therapeutic effect is difficult to evaluate not only because of clinically and hitherto also technically poor accessability of the brain but also because of differences in tumour classification systems, and consequently limited comparability. There is however definite knowledge on the effectiveness of several single drugs as well as strong evidence on the effectiveness of some polychemotherapeutic programs. The measure of success presently is rather prolongation of survival time for months than a change in cure rate. A general recommendation for the cytostatic treatment of brain tumors may not be given in that situation, but within a clinical study the use of cytostatic agents seems promising anyway.

Antineoplastic Agents↗
PubMed1977

[Chemotherapy of osteosarcoma (author's transl)].

The cyclic chemotherapy scheme OS I/75 was tried in 6 patients with newly diagnosed osteosarcoma and in 3 patients with secondary metastases. The treatment consists of high dose methotrexate, followed by citrovorum-factor rescue, doxorubicine (Adriblastin) and cyclophosphamide (Endoxan). All 6 primary patients are in a continuous remission of 6+ to 21+ months (median 12+ months). The length of remission in the patients with metastases is 5.5+ and 8+ months. The haematological side effects led to an average prolongation of the cycle by 11 days in a planned cycle duration of 42 days. However, they were readily manageable. Among the other side effects two cases of Adriblastin myocardiopathy are remarkable which became apparent after methotrexate and ifosfamide. In order to improve possibilities for treatment regional centralisation of patient care and interdisciplinary and supraregional cooperation of treatment centres are necessary. A prospective treatment programme has been developed for the Federal Republic of Germany and Austria.

Adolescent↗